TG Therapeutics TGTX Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's change in AP?
- TG Therapeutics (TGTX) reported change in AP of $34.02M in Q1 2026.
- How has TG Therapeutics's change in AP changed year-over-year?
- TG Therapeutics's change in AP decreased by 47.8% year-over-year, from $65.18M to $34.02M.
- What is the long-term trend for TG Therapeutics's change in AP?
- Over 2 years (2021 to 2023), TG Therapeutics's change in AP has grown at a -89.0% compound annual growth rate (CAGR), from $15.99M to $192K.
- What does change in AP mean?
- The net change in the amount of money the company owes to its suppliers.
- How do you interpret change in AP?
- An increase in payables can signal improved cash management by delaying payments, while a decrease may indicate faster settlement of obligations.
- How does change in AP compare across companies?
- Standard metric used to calculate Days Payable Outstanding (DPO) across all industries.